NCT06319196View on ClinicalTrials.gov

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

February 15, 2027

Study Completion Date

February 15, 2030

Conditions
Cutaneous MelanomaMelanoma Stage IVMucosal Melanoma
Interventions
DRUG

Opdualag

Opdualag vial IV every 4 weeks (Q4W)

DRUG

Nivolumab

Nivolumab 480mg IV Q4W

Trial Locations (1)

M5G 1Z5

RECRUITING

UHN- Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT06319196 - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | Biotech Hunter | Biotech Hunter